. 2021 May 5;9:558285. doi: 10.3389/fcell.2021.558285

TABLE 3.

Evaluation for cross-section and flexural strength related to age and presence or not of alendronate.

Age	Alendronate	Cross-section (mm2) fracture Mean ± SD	Cross-section (mm2) no fracture Mean ± SD	Flexural strength (MPa) fracture Mean ± SD	Flexural strength (MPa) no fracture Mean ± SD
Middle-age	No (O)	51.70 ± 22.37^Aa	20.30 ± 2.32 ^Ab	4.21 ± 2.87 ^Bb	80.43 ± 33.49 ^Aa
	Yes (OA)	55.35 ± 28.78 ^Aa	19.89 ± 4.01 ^Ab	13.67 ± 16.42 ^ABb	72.25 ± 18.03 ^Aa
Young	No (Y)	25.45 ± 4.33 ^Aa	12.87 ± 2.01 ^Bb	24.50 ± 9.95 ^ABb	112.09 ± 0.25 ^Aa
	Yes (YA)	37.40 ± 17.34 ^Aa	16.68 ± 1.89 ^ABb	27.37 ± 23.45 ^Ab	83.64 ± 25.10 ^Aa

Lower case letters (a, b) are used, for each group (age and use of alendronate), to indicate significant differences when comparing the conditions (fracture x no fracture) (p < 0.05). In each line, when the same lower case letter is used, the difference between the means is not statistically significant. Uppercase letters (A, B) are used, for each condition (fracture and no fracture), to indicate significant differences when comparing the groups (age and use of alendronate) (p < 0.05). In each column, when the same uppercase letter is used, the difference between the means is not statistically significant.